Concordant effects of aromatase inhibitors on gene expression in ER+ rat and human mammary cancers and modulation of the proteins coded by these genes

Cancer Prevention Research

Volumn 6, Issue 11, 2013, Pages 1151-1161

  Lu, Yan ^a   You, Ming ^a   Ghazoui, Zara ^b   Liu, Pengyuan ^a   Vedell, Peter T ^a   Wen, Weidong ^c   Bode, Ann M ^d   Grubbs, Clinton J ^e   Lubet, Ronald A ^f  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d University of Minnesota Hormel Institute   (United States)

^e University of Alabama at Birmingham   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; AURORA A KINASE; BURB1 PROTEIN; CHLORMETHINE; CYCLIN A; CYCLIN A2; CYCLIN B; CYCLIN DEPENDENT KINASE 1; ESTROGEN RECEPTOR; LETROZOLE; PTTG PROTEIN; TOP2 PROTEIN; TPX 2 PROTEIN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; VOROZOLE;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN MCF 7; CHROMOSOME CONDENSATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENETIC CODE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMETAPHASE; PROTEIN EXPRESSION; RAT;

ANIMALS; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MAMMARY NEOPLASMS, EXPERIMENTAL; NITRILES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 84887878472     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0126     Document Type: Article

References (34)

1. Jordan VC. Effects of tamoxifen in relation to breast cancer. Br Med J 1977;1:1534-5. (Pubitemid 8115362)
2. Herold CI, Blackwell KL. Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease. Clin Breast Cancer 2008;8:50-64. (Pubitemid 351346230)
3. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. ATAC Trialist' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9. (Pubitemid 34694019)
4. Breast International Group (BIG) 1-98 Collaborative Group Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57.
5. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wene J, et al. Exemestane for breast cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-91.
6. Goss PE, Winer EP, Tannock IF, Schwartz LH. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor Vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. J Clin Oncol 1999;17:52-63. (Pubitemid 29022378)
7. Goss PE. Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor. Breast Cancer Res Treat 1998;49(Suppl 1):S59-65.
8. Huggins C, Briziarelli G, Sutton H Jr. Rapid induction of mammary carcinoma in the rat and the influence of hormones on the tumors. J Exp Med 1959;109:25-42.
9. Huggins CB, Ueda N, Wiessler M. N-Nitroso-N-methylurea elicits mammary cancer in resistant and sensitive rat strains. Proc Natl Acad Sci U S A 1981;78:1185-8. (Pubitemid 11102185)
10. Chan MM, Lu X, Merchant FM, Iglehart JD, Miron PL. Gene expression profiling of NMU-induced rat mammary tumors: cross species comparison with human breast cancer. Carcinogenesis 2005;26:1343-53. (Pubitemid 41417876)
11. Lubet RA, Steele VE, Casebolt TL, Eto I, Kelloff GJ, Grubbs CJ. Chemopreventive effects of the aromatase inhibitors Vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis 1994;15:2775-80.
12. Van Ginckel R, Janssens B, Callens M, Goeminne N, Wouters L, DeCoster R. Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a)anthracent-induced mammary carcinoma in the rat. Cancer Chemother Pharmacol 1996;38:21-8.
13. Lubet RA, Steele VE, DeCoster R, Bowden C, You M, Juliana MM, et al. Chemopreventive effects of the aromatase inhibitor Vorozole (R83842) in the methylnitrosourea-induced mammary cancer model. Carcinogenesis 1998;19:1345-51. (Pubitemid 28409829)
14. Christov K, Shilkaitis A, Green A, Mehta RG, Grubbs C, Kelloff G, et al. Cellular responses of mammary carcinomas to aromatase inhibitors: effects of Vorozole. Breast Cancer Res Treat 2000;60:117-28. (Pubitemid 30307471)
15. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffin C, Boeddinghaus I, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer - a study from the IMPACT trialist. J Clin Oncol 2005;23:2477-92. (Pubitemid 47050838)
16. Affymetrix® Expression Console™ Software. (Affymetrix, 2012) [accessed 2013 Oct 31]. Available from http://www.affymetrix.com/estore/browse/ level-seven-software-products-only.jsp?productId=131414#1-1.
17. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
18. Broad Institute GSEA and MSigDB Team. Gene set enrichment analysis, vol. 2012. 2012 [accessed 2012 Apr 18]. Available from: www.broad.mit.edu/gsea.
19. Broad Institute GSEA and MSigDB Team. Molecular signatures database v3.0, vol. 2012. 2012 [accessed 2012 Apr 18]. Available from: www.broad.mit.edu/gsea/ msigdb/msigdb-index.html.
20. Reich M, Ohm K, Angelo M, Tamayo P, Mesirov JP. GeneCluster 2.0: an advanced toolset for bioarray analysis. Bioinformatics 2004;20:1797-8. (Pubitemid 39162057)
21. Thomson Reuters. MetaCore. in GeneGo, vol. 2012. 2012. Available from: www.genego.com/.
22. Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, Murray J, et al. Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor letrozole. Pharmacogenet Genomics 2007;17:813-26. (Pubitemid 47462295)
23. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009;106:13820-5.
24. Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, et al. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 2007;9:R37.
25. Wacnik PW, Baker CM, Herron MJ, Kren BT, Blazer BR, Wilcox GL, et al. Tumor-induced mechanical hyperalgesia involves CGRP receptors and altered innervation and vascularization of DsRed2 fluorescent hindpaw tumors. Pain 2005;115:95-106.
26. Ghazoui Z, Buffa FM, Dunbier AK, Anderson H, Dexter T, Detre S, et al. Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer. Clin Cancer Res 2011;17:3005-12.
27. Stender JD, Frasor J, Komm B, Chang KC, Kraus WL, Katzenellenbogen BS. Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Mol Endocrinol 2007;21:2112-23. (Pubitemid 47347376)
28. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, et al. Genome wide analysis of estrogen receptor binding sites. Nat Genet 2006;38:1289-97. (Pubitemid 44646291)
29. Lubet RA, Gordon G, Prough RA, Lei XD, You M, Wang Y, et al. Modulation of methylnitrosourea-induced breast cancer in Sprague Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutations. Cancer Res 1998;58:921-6. (Pubitemid 28182459)
30. Christov K, Grubbs CJ, Shilkatis A, Juliana MM, Lubet RA. Short term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model. Clin Cancer Res 2007;13:5488-96. (Pubitemid 47510377)
31. Miller TW, Balko JM, Fox EM, Ghazoul Z, Dunbier A. ERα-dependent E2F transcription can mediate resistance to estrogen deprivaion in human breast cancer. Cancer Discov 2011;1:338-351.
32. Fabian CJ, Kimler BF. Use of biomarkers for breast cancer risk assessment and prevention. J Steroid Biochem Mol Biol 2007;106:31-9. (Pubitemid 47362645)
33. Fabian CJ, Kimler BF, Zalles CM, Khan QJ, Mayo MS, Phillips TA, et al. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. Breast Cancer Res Treat 2007;106:75-84. (Pubitemid 47498093)
34. Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, Langdon SP. Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecol Oncol 2007;106:461-8. (Pubitemid 47302473)